PHOENIX and LEESBURG, Fla., May 24, 2022 / PRNewswire / – Thesis Biosciences, the leader in targeted genetic sequencing, has been selected by Pathways Health Partners (PHP), the healthcare organization responsible for addressing the challenges facing healthcare today (ACO), to provide membership practices to future generations. sequencing (NGS) testing and precision medicine services to detect and prevent chronic and inherited diseases in patients.
Founded in 2018, PHP deploys integrated capabilities to support value-based care. The company’s care management services focus on where they can have the greatest impact on health outcomes, while its technology platform predicts which patients may have serious and preventable medical conditions. PHP’s analytical capabilities measure real-time performance, cost, risk, and productivity with strategies and goals to avoid unnecessary spending and close attention gaps to improve member quality scores.
“The practices of Pathways Health Partners members are committed to improving the health outcomes of individuals and the population through preventive care,” he said. Ron King, Director General of Thesis Biosciences. “We are pleased to increase the clinical specialization of PHP members through our targeted genetic testing capabilities, which will enhance our ability to provide proactive and individualized care while effectively managing costs and resource use.”
Ninety percent $ 3.8 trillion Annual spending on health care in the U.S. is for people with chronic illnesses and mental health problems, according to the Centers for Disease Control and Prevention (CDC). A 2018 study of chronic diseases in the U.S. shows that 45% of all Americans have at least one chronic illness, and one in four has at least two chronic conditions.
“Thesis Biosciences’ NGS testing and specialization in precision medicine will be essential for our ACO members to develop accurate and effective patient care plans based on their unique genetic makeup, ”he said. Scott Baker, CEO of Pathways Health Partners. “Collaborating with Thesis allows us to improve the quality of the clinical services our members provide to patients, which will lead to better health outcomes and lower costs of care.”
ACOs are teams of physicians, hospitals, and other health care providers who volunteer to provide coordinated, high-quality, coordinated care to their Medicare patients. When ACOs manage to provide high-quality care and spend more health care dollars more wisely, members share in the savings they get from the Medicare program. As of January 2022, there are 483 Medicare ACOs serving more than 11 million beneficiaries, according to the National Association of ACOs. Since 2010, more than 1,200 organizations have participated in ACO contracts in the Medicare, Medicaid, and commercial sectors.
Pharmacogenetics and hereditary markers are playing an increasingly critical role in preventive medicine. Enabling optimized genetics-based care plans empowers physicians, patients, and families to make more preventive and treatment decisions about chronic and inherited diseases such as cancer, heart disease, lung disease, diabetes, and Alzheimer’s. For example, NGS tests can see if a person is at high risk for peripheral vascular disease or coronary artery disease. These types of approaches allow clinicians to educate patients about lifestyle choices that can minimize the impact of hereditary conditions.
Thesis Biosciences provides physicians, hospitals, and researchers with tools, including advanced genetic testing, to help patients overcome and prevent major chronic diseases such as cancer, heart and lung disease, diabetes, and Alzheimer’s disease. Thesis also works with medical device and drug device manufacturers to help reduce the risk of clinical trials and provide better diagnostic results.
For more information on Thesis Biosciences, visit www.tesisbiosciences.com.
Thesis on Biosciences
Thesis has overturned genetic sequencing directed by the genetically integrated medicine platform of Biosciences. Our mission is to change medicine by providing tools to physicians, hospitals, and researchers to help patients treat and overcome major chronic diseases, such as heart and lung disease, cancer, and Alzheimer’s, through advanced genetic testing. The dissertation provides health care providers and physicians with access to our special genetic testing and precision medicine, enabling them to create personalized care plans to treat chronic diseases, individually and for generations to come. We also provide medical device and pharmaceutical companies with the opportunity to bring new products to market and create a strong repository of genetic data and research. Visit www.tesisbiosciences.com to learn more.
About Pathways Health Partners
Pathways Health Partners provides access to cutting-edge data analysis, proven workflows, unparalleled industry experience, strong payer relationships and practical local support from dedicated experts to more than 350 preferred primary care and specialty care providers. Our goal is to make your primary care practice or health center a success in a value-based healthcare ecosystem that promotes better outcomes for patients and supports a high-performing, high-value health care system for your community. Visit https://pathwayshp.com for more information.
Amendola Communications Thesis on behalf of Biosciences
View original media for download: https://www.prnewswire.com/news-releases/tesis-biosciences-to-provide-genetic-testing-services-for-florida-aco-pathways-health-partners-301553444.html
SOURCE Thesis Biosciences